JP2016504284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504284A5 JP2016504284A5 JP2015542870A JP2015542870A JP2016504284A5 JP 2016504284 A5 JP2016504284 A5 JP 2016504284A5 JP 2015542870 A JP2015542870 A JP 2015542870A JP 2015542870 A JP2015542870 A JP 2015542870A JP 2016504284 A5 JP2016504284 A5 JP 2016504284A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- alkynyl
- independently
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 99
- 229910052799 carbon Inorganic materials 0.000 claims 95
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims 55
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 49
- 150000004820 halides Chemical class 0.000 claims 47
- -1 aminothionyl Chemical group 0.000 claims 44
- 125000003118 aryl group Chemical group 0.000 claims 41
- 125000001072 heteroaryl group Chemical group 0.000 claims 39
- 125000003710 aryl alkyl group Chemical group 0.000 claims 36
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 31
- 150000001540 azides Chemical class 0.000 claims 29
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims 29
- 229910052757 nitrogen Inorganic materials 0.000 claims 21
- 125000000304 alkynyl group Chemical group 0.000 claims 16
- 125000003342 alkenyl group Chemical group 0.000 claims 15
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 241000700605 Viruses Species 0.000 claims 13
- 229910052760 oxygen Inorganic materials 0.000 claims 13
- 229910052717 sulfur Inorganic materials 0.000 claims 13
- 125000004001 thioalkyl group Chemical group 0.000 claims 12
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 11
- 125000004414 alkyl thio group Chemical group 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 241000712431 Influenza A virus Species 0.000 claims 3
- 241000713196 Influenza B virus Species 0.000 claims 3
- 241001115401 Marburgvirus Species 0.000 claims 3
- 241000710772 Yellow fever virus Species 0.000 claims 3
- 229940051021 yellow-fever virus Drugs 0.000 claims 3
- 241000725619 Dengue virus Species 0.000 claims 2
- 241001115402 Ebolavirus Species 0.000 claims 2
- 241000709661 Enterovirus Species 0.000 claims 2
- 241000712890 Junin mammarenavirus Species 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 2
- 241000713124 Rift Valley fever virus Species 0.000 claims 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 2
- 241000712908 Tacaribe mammarenavirus Species 0.000 claims 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 2
- 241000710886 West Nile virus Species 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 241000712892 Arenaviridae Species 0.000 claims 1
- 241001493160 California encephalitis virus Species 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241000709687 Coxsackievirus Species 0.000 claims 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 241000711950 Filoviridae Species 0.000 claims 1
- 241000710781 Flaviviridae Species 0.000 claims 1
- 241000190708 Guanarito mammarenavirus Species 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 206010023927 Lassa fever Diseases 0.000 claims 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims 1
- 241000712898 Machupo mammarenavirus Species 0.000 claims 1
- 241000150452 Orthohantavirus Species 0.000 claims 1
- 241000712464 Orthomyxoviridae Species 0.000 claims 1
- 241000711504 Paramyxoviridae Species 0.000 claims 1
- 241000150350 Peribunyaviridae Species 0.000 claims 1
- 241000709664 Picornaviridae Species 0.000 claims 1
- 241000713126 Punta Toro virus Species 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 241000710924 Togaviridae Species 0.000 claims 1
- 241000700647 Variola virus Species 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000710951 Western equine encephalitis virus Species 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 *C1=CN=C(*)NC1=* Chemical compound *C1=CN=C(*)NC1=* 0.000 description 155
- DNLJAPGUAPBXHE-RXDXJJGDSA-N CO[C@H]1[C@H](c2c[nH]c3c2ncnc3N)N[C@H](CO)[C@H]1O Chemical compound CO[C@H]1[C@H](c2c[nH]c3c2ncnc3N)N[C@H](CO)[C@H]1O DNLJAPGUAPBXHE-RXDXJJGDSA-N 0.000 description 2
- LLXZUZLCCNNAOM-JKUQZMGJSA-N C[C@@H](C1)N[C@H](CO)[C@H]1O Chemical compound C[C@@H](C1)N[C@H](CO)[C@H]1O LLXZUZLCCNNAOM-JKUQZMGJSA-N 0.000 description 2
- GUFBLOGHOCWZCD-POYBYMJQSA-N Nc1c2[nH]cc([C@@H]3N[C@H](CO)CC3)c2ncn1 Chemical compound Nc1c2[nH]cc([C@@H]3N[C@H](CO)CC3)c2ncn1 GUFBLOGHOCWZCD-POYBYMJQSA-N 0.000 description 2
- RSYWBFOPJYGRMR-GEVIPFJHSA-N Nc1c2[nH]cc([C@@H]3N[C@H](CO)C[C@@H]3F)c2ncn1 Chemical compound Nc1c2[nH]cc([C@@H]3N[C@H](CO)C[C@@H]3F)c2ncn1 RSYWBFOPJYGRMR-GEVIPFJHSA-N 0.000 description 2
- OBIXMCRFEXZXER-ARDNSNSESA-N Nc1c2[nH]cc([C@@H]3N[C@H](CO)C[C@H]3O)c2ncn1 Chemical compound Nc1c2[nH]cc([C@@H]3N[C@H](CO)C[C@H]3O)c2ncn1 OBIXMCRFEXZXER-ARDNSNSESA-N 0.000 description 2
- HTKJHJQGNWKVRD-HQMQMISQSA-N Nc1ncnc2c1NCC2[C@@H](C1(F)F)N[C@H](CO)[C@H]1O Chemical compound Nc1ncnc2c1NCC2[C@@H](C1(F)F)N[C@H](CO)[C@H]1O HTKJHJQGNWKVRD-HQMQMISQSA-N 0.000 description 2
- WSYRZIZYUWPOLP-RGOKHQFPSA-N C#CC(C=C1[C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C(N)NC1=O Chemical compound C#CC(C=C1[C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C(N)NC1=O WSYRZIZYUWPOLP-RGOKHQFPSA-N 0.000 description 1
- DWELXPFRAWEKLB-XAVMHZPKSA-N CC(C(N1)=O)=CC([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C1O Chemical compound CC(C(N1)=O)=CC([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C1O DWELXPFRAWEKLB-XAVMHZPKSA-N 0.000 description 1
- WAPKAXXJFRIDCE-XAVMHZPKSA-N CC(C=C1[C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C(N)NC1=O Chemical compound CC(C=C1[C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C(N)NC1=O WAPKAXXJFRIDCE-XAVMHZPKSA-N 0.000 description 1
- FMIRQNOVTQGDEW-RGOKHQFPSA-N CCC(C=C1[C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C(N)NC1=O Chemical compound CCC(C=C1[C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C(N)NC1=O FMIRQNOVTQGDEW-RGOKHQFPSA-N 0.000 description 1
- CHQVICWFDPEJOK-UCROKIRRSA-N NC(C([C@@H]([C@@H]1O)N[C@H](CO)[C@H]1O)=CN1)=NC1=O Chemical compound NC(C([C@@H]([C@@H]1O)N[C@H](CO)[C@H]1O)=CN1)=NC1=O CHQVICWFDPEJOK-UCROKIRRSA-N 0.000 description 1
- CPOLMWXQKHMDTG-JYFAAPFMSA-N NC(N1)=CC=C([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)C1=O Chemical compound NC(N1)=CC=C([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)C1=O CPOLMWXQKHMDTG-JYFAAPFMSA-N 0.000 description 1
- VXCZUOGLGVWRIR-ZUMNNYEFSA-N NC(N1)=NC=C(C([C@@H]2O)N[C@H](CO)[C@H]2O)C1=O Chemical compound NC(N1)=NC=C(C([C@@H]2O)N[C@H](CO)[C@H]2O)C1=O VXCZUOGLGVWRIR-ZUMNNYEFSA-N 0.000 description 1
- ABQFSPSUNQYJRN-HWBGAQDOSA-N NC(NC(C(C([C@@H]1O)N[C@H](CO)[C@H]1O)=C1)=O)=C1F Chemical compound NC(NC(C(C([C@@H]1O)N[C@H](CO)[C@H]1O)=C1)=O)=C1F ABQFSPSUNQYJRN-HWBGAQDOSA-N 0.000 description 1
- OVLGEFNKTPVUHW-NEPJDUFXSA-N Nc1ccc([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)cn1 Chemical compound Nc1ccc([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)cn1 OVLGEFNKTPVUHW-NEPJDUFXSA-N 0.000 description 1
- UMFCMUAQLLZTAO-MIRRECJXSA-N Nc1nc(O)c([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)c(O)n1 Chemical compound Nc1nc(O)c([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)c(O)n1 UMFCMUAQLLZTAO-MIRRECJXSA-N 0.000 description 1
- CJCSSIACHRZLAQ-VVXQKDJTSA-N OC[C@H]([C@H](C1)O)NC1C1=CN=CNC1=O Chemical compound OC[C@H]([C@H](C1)O)NC1C1=CN=CNC1=O CJCSSIACHRZLAQ-VVXQKDJTSA-N 0.000 description 1
- FEYBDKGNVYMXKY-FXWAIPRXSA-N OC[C@H]([C@H]([C@H]1O)O)NC1C(C=CC(N1)=O)=C1O Chemical compound OC[C@H]([C@H]([C@H]1O)O)NC1C(C=CC(N1)=O)=C1O FEYBDKGNVYMXKY-FXWAIPRXSA-N 0.000 description 1
- XKRKHLSUXIRKHX-UCROKIRRSA-N OC[C@H]([C@H]([C@H]1O)O)N[C@H]1C(C(N1)=O)=COC1=O Chemical compound OC[C@H]([C@H]([C@H]1O)O)N[C@H]1C(C(N1)=O)=COC1=O XKRKHLSUXIRKHX-UCROKIRRSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727468P | 2012-11-16 | 2012-11-16 | |
| US61/727,468 | 2012-11-16 | ||
| PCT/US2013/070537 WO2014078778A2 (en) | 2012-11-16 | 2013-11-18 | Antiviral azasugar-containing nucleosides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016504284A JP2016504284A (ja) | 2016-02-12 |
| JP2016504284A5 true JP2016504284A5 (enExample) | 2017-01-12 |
Family
ID=50731836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542870A Pending JP2016504284A (ja) | 2012-11-16 | 2013-11-18 | 抗ウイルス性アザ糖を含有するヌクレオシド |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150291596A1 (enExample) |
| EP (2) | EP3251674A3 (enExample) |
| JP (1) | JP2016504284A (enExample) |
| AU (1) | AU2013344422A1 (enExample) |
| CA (1) | CA2890905A1 (enExample) |
| HK (1) | HK1212235A1 (enExample) |
| IL (1) | IL238785A0 (enExample) |
| MX (1) | MX2015005949A (enExample) |
| WO (1) | WO2014078778A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20130862T1 (hr) | 2009-09-21 | 2013-10-25 | Gilead Sciences, Inc. | Procesi i intermedijeri za pripravu analoga 1'-cijanokarbanukleozida |
| UA111163C2 (uk) | 2010-07-22 | 2016-04-11 | Гайлід Сайєнсіз, Інк. | Способи й сполуки для лікування вірусних інфекцій paramyxoviridae |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| AU2016216673B2 (en) | 2015-03-04 | 2017-02-02 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| MA52371A (fr) * | 2015-09-16 | 2021-09-22 | Gilead Sciences Inc | Méthodes de traitement d'infections dues aux coronaviridae |
| TW201725203A (zh) | 2015-12-16 | 2017-07-16 | 必治妥美雅史谷比公司 | 作為ａｐｊ受體促效劑之雜芳基羥基嘧啶酮 |
| WO2017172596A1 (en) | 2016-03-28 | 2017-10-05 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| CA3056072C (en) | 2017-03-14 | 2022-08-23 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| CN106834546A (zh) * | 2017-03-20 | 2017-06-13 | 杭州迪安医学检验中心有限公司 | 一种基于熔解曲线法单管同时检测多种呼吸道病毒的引物及其应用 |
| JP2020518578A (ja) | 2017-05-01 | 2020-06-25 | ギリアード サイエンシーズ， インコーポレイテッド | （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態 |
| ES3000461T3 (en) | 2017-07-11 | 2025-02-28 | Gilead Sciences Inc | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| CN109053788A (zh) * | 2018-09-20 | 2018-12-21 | 山东谛爱生物技术有限公司 | 一种吡唑类化合物的制备方法 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ， インコーポレイテッド | ＳＡＲＳ ＣｏＶ－２感染を治療するための方法 |
| TWI890963B (zh) | 2020-03-12 | 2025-07-21 | 美商基利科學股份有限公司 | 1'-氰基核苷之製備方法 |
| AU2021251689B2 (en) | 2020-04-06 | 2024-06-13 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| TW202532084A (zh) | 2020-05-29 | 2025-08-16 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
| IL299202A (en) | 2020-06-24 | 2023-02-01 | Gilead Sciences Inc | 1'-cyano nucleoside analogs and uses thereof |
| CN111704619B (zh) * | 2020-07-30 | 2021-10-19 | 四川大学 | 一种Forodesine的制备方法 |
| PE20231983A1 (es) | 2020-08-27 | 2023-12-12 | Gilead Sciences Inc | Compuestos y metodos para el tratamiento de infecciones virales |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| CN114588159A (zh) * | 2020-12-07 | 2022-06-07 | 成都傲科新技术有限责任公司 | 一种治疗猫冠状病毒感染的化合物及其应用 |
| JPWO2022270628A1 (enExample) * | 2021-06-25 | 2022-12-29 | ||
| PE20240654A1 (es) * | 2021-08-20 | 2024-04-04 | Shionogi & Co | Derivados de nucleosido y profarmacos de los mismos que tienen accion inhibidora del crecimiento viral |
| CN113666941B (zh) * | 2021-09-01 | 2023-03-10 | 浙江珲达生物科技有限公司 | 一种2,3-O-异亚丙基-D-核糖酸-γ-内酯的重结晶方法 |
| CA3244278A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3719667A (en) | 1970-08-24 | 1973-03-06 | Lilly Co Eli | Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters |
| US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP0630904A4 (en) * | 1992-08-26 | 1995-01-04 | Japan Tobacco Inc. | Novel nicotine derivative. |
| US7098334B2 (en) * | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| AU2003233667A1 (en) * | 2002-05-23 | 2003-12-12 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof |
| EP1544294B8 (en) * | 2002-07-17 | 2014-03-19 | Riken | Nucleosides or nucleotides having novel unnatural bases and use thereof |
| WO2004050676A1 (ja) | 2002-12-04 | 2004-06-17 | Mitsubishi Gas Chemical Company, Inc. | フッ素化方法 |
| US6780993B1 (en) * | 2003-02-19 | 2004-08-24 | Biocryst Pharmaceuticals, Inc. | Preparation of deazaguanine analog |
| MY139887A (en) | 2004-04-02 | 2009-11-30 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same. |
| US7560434B2 (en) * | 2004-06-22 | 2009-07-14 | Biocryst Pharmaceuticals, Inc. | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| KR20070100237A (ko) * | 2004-10-29 | 2007-10-10 | 바이오크리스트 파마수티컬즈, 인코퍼레이티드 | 치료용 푸로피리미딘 및 티에노피리미딘 |
| DK1891038T3 (da) * | 2005-05-13 | 2009-01-19 | Lilly Co Eli | Substituerede n-arylpyrrolidiner som selektive androgenreceptormodulatorer |
| CA2618335C (en) * | 2005-08-15 | 2015-03-31 | F.Hoffmann-La Roche Ag | Antiviral phosphoramidates of 4'-substituted pronucleotides |
| EP1951244A4 (en) * | 2005-11-22 | 2010-08-25 | Glaxosmithkline Llc | CALCILYTIC COMPOUNDS |
| MX2008007103A (es) | 2005-12-02 | 2008-09-12 | Bayer Healthcare Llc | Derivados 4-amino-pirrolotriazina sustituidos, útiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis. |
| US7829584B2 (en) | 2006-03-21 | 2010-11-09 | Janssen Pharmaceutica Nv | Pyridines and pyridine N-oxides as modulators of thrombin |
| US8030322B2 (en) | 2006-04-27 | 2011-10-04 | Glaxo Group Limited | Spirocompounds useful as modulators for dopamine D3 receptors |
| SG177974A1 (en) * | 2007-01-12 | 2012-02-28 | Biocryst Pharm Inc | Antiviral nucleoside analogs |
| CA2685520A1 (en) * | 2007-05-10 | 2008-11-20 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer |
| EP2313102A2 (en) * | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| EP2348854A4 (en) * | 2008-09-22 | 2012-03-14 | Einstein Coll Med | METHOD AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS BY INHIBITING THE "QUORUM SENSING |
| WO2011094450A1 (en) | 2010-01-27 | 2011-08-04 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules |
| WO2011132017A1 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Pyrido[3,4-d]pyrimidinyl acetamide derivatives as trpa1 modulators |
| EP2627334B1 (en) * | 2010-10-15 | 2015-04-29 | Biocryst Pharmaceuticals, Inc. | Compositions for use in the treatment of viral infections |
| AR090699A1 (es) * | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
-
2013
- 2013-11-18 EP EP17162146.9A patent/EP3251674A3/en not_active Withdrawn
- 2013-11-18 AU AU2013344422A patent/AU2013344422A1/en not_active Abandoned
- 2013-11-18 EP EP13855441.5A patent/EP2919785A4/en not_active Withdrawn
- 2013-11-18 JP JP2015542870A patent/JP2016504284A/ja active Pending
- 2013-11-18 CA CA2890905A patent/CA2890905A1/en not_active Abandoned
- 2013-11-18 HK HK16100301.6A patent/HK1212235A1/xx unknown
- 2013-11-18 MX MX2015005949A patent/MX2015005949A/es unknown
- 2013-11-18 WO PCT/US2013/070537 patent/WO2014078778A2/en not_active Ceased
- 2013-11-18 US US14/441,762 patent/US20150291596A1/en not_active Abandoned
-
2015
- 2015-05-13 IL IL238785A patent/IL238785A0/en unknown
-
2017
- 2017-03-31 US US15/475,507 patent/US20170267681A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504284A5 (enExample) | ||
| JP2013544788A5 (enExample) | ||
| JP2015514772A5 (enExample) | ||
| HRP20150487T1 (hr) | Kompozicije za primjenu u lijeäśenju virusnih infekcija | |
| JP2025098020A5 (enExample) | ||
| WO2007103111A8 (en) | Antiviral drugs for treatment of arenavirus infection | |
| NZ596014A (en) | Dihydroorotate - dehydrogenase inhibitors as virostatic compounds | |
| JP2011516610A5 (enExample) | ||
| IL277160B1 (en) | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| JP2016518305A5 (enExample) | ||
| CY1115253T1 (el) | Κρυσταλλικες μορφες ενος παραγωγου 2-θειαζολυλο-4-κινολινυλ-οξυ-ομαδας, ενος ισχυρου αναστολεα του ηcv | |
| JP2013537203A5 (enExample) | ||
| JP2015517555A5 (enExample) | ||
| JP2013512915A5 (enExample) | ||
| RU2014106765A (ru) | Производные витамина в6 нуклеотидов, ациклических нуклеотидов и ациклических нуклеозидных фосфонатов | |
| WO2014106019A3 (en) | Novel antiviral agents against hbv infection | |
| JP2009535352A5 (enExample) | ||
| NZ597544A (en) | Modified 4'-nucleosides as antiviral agents | |
| WO2008100447A3 (en) | Nucleoside analogs for antiviral treatment | |
| JP2013503880A5 (enExample) | ||
| JP2018135343A5 (enExample) | ||
| JP2014530837A5 (enExample) | ||
| MX363405B (es) | Derivados de indanona, sales farmaceuticamente aceptables o isomeros opticos de los mismos, metodo de preparacion de los mismos, y composiciones farmaceuticas que contienen los mismos como ingrediente activo para prevención o tratamiento de enfermedades virales. | |
| JP2013503881A5 (enExample) | ||
| JP2012518649A5 (enExample) |